He was most recently the president and CEO of Aptinyx (NASDAQ: APTX), a clinical-stage CNS-focused biotech company. His previous experience includes senior leadership roles at Baxter International (NYSE: BAX) and The Boston Consulting Group.
“We are excited to welcome Andy to the Tentarix team at this critical inflection point for the company,” said Tentarix Chairman Donald Santel. “Under Andy’s leadership, we are poised to effectively execute on our existing partnered programs with Gilead and AbbVie, and to rapidly build and advance our internal pipeline of programs in the near-term.”
"I am honored to join Tentarix at such a pivotal time in its journey," said Mr. Kidd. "I firmly believe in the company's mission to revolutionize patient care through multi-specific biologic treatments. The compelling science behind the Tentacles™ platform presents an unparalleled opportunity to impact the lives of patients globally.
I am committed to harnessing this potential, driving forward our strategic initiatives, and building on the strong foundation laid by the Tentarix team to deliver on our promise of transforming the landscape of precision oncology and immunology."
About Tentarix Biotherapeutics:
Tentarix's mission is to develop first-in-class targeted, multifunctional, conditional therapies across a range of indications of high unmet medical need. Tentarix is focused on modulating cell specific functions while increasing the safety profile for biologics. Tentarix has built a team that aims to transform research and development through understanding complex immune interactions (CellSurf™), discovery of novel human antibodies (HuTARG™), and high-throughput screening of conditional multi-specifics (FunctionSeq™).
For more information, please visit www.tentarix.com.
